Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis.
作者： T. Langenegger , P. Wahl , D. Schiesser , B. Thürlimann
DOI: 10.1007/S10549-006-9243-7
关键词:
摘要: Endocrine therapy for hormone-sensitive breast cancer is a well-established treatment option, both in adjuvant and palliative settings. For patients undergoing chronic hemodialysis, only scant pharmacokinetic data have been published tamoxifen, no anastrozole. We therefore measured plasma levels of its major metabolite, N-desmethyl anastrozole patient hemodialysis. Clinical tolerability was good. The blood tamoxifen were within the expected therapeutic ranges. From this study, we can conclude that endocrine with or seems feasible safe
springer.com
sci-hub.se 参考文章(13)
I B Pisoni, P M Allaria, E Gandini, A Giangrande, Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent? Journal of Nephrology. ,vol. 12, pp. 395- 397 ,(1999)
Hetal R Sheth, Gwyn Lord, Katherine Tkaczuk, Malcolm Danton, Lynn M Lewis, Patricia Langenberg, Chang K Lim, Jodi Anne Flaws, None, Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients. Journal of Womens Health. ,vol. 12, pp. 799- 808 ,(2003) , 10.1089/154099903322447765
, Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. British Journal of Cancer. ,vol. 85, pp. 317- 324 ,(2001) , 10.1054/BJOC.2001.1925
Andrea Decensi, Sara Gandini, Aliana Guerrieri-Gonzaga, Harriet Johansson, Lapo Manetti, Bernardo Bonanni, Maria Teresa Sandri, Antonella Barreca, Alberto Costa, Chris Robertson, Ernst A. Lien, Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. Journal of Clinical Oncology. ,vol. 17, pp. 2633- 2638 ,(1999) , 10.1200/JCO.1999.17.9.2633
Per Lønning, Christian Pfister, Andrea Martoni, Claudio Zamagni, Pharmacokinetics of third-generation aromatase inhibitors Seminars in Oncology. ,vol. 30, pp. 23- 32 ,(2003) , 10.1016/S0093-7754(03)00305-1
Riccardo Maria Fagugli, Rita De Smet, Umberto Buoncristiani, Norbert Lameire, Raymond Vanholder, Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis American Journal of Kidney Diseases. ,vol. 40, pp. 339- 347 ,(2002) , 10.1053/AJKD.2002.34518
Aman U. Buzdar, John F. R. Robertson, Wolfgang Eiermann, Jean-Marc Nabholtz, An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane Cancer. ,vol. 95, pp. 2006- 2016 ,(2002) , 10.1002/CNCR.10908
H. Kim Crewe, Lisa M. Notley, Rebecca M. Wunsch, Martin S. Lennard, Elizabeth M. J. Gillam, Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metabolism and Disposition. ,vol. 30, pp. 869- 874 ,(2002) , 10.1124/DMD.30.8.869
Karla C. Morello, Gregory T. Wurz, Michael W. DeGregorio, Pharmacokinetics of selective estrogen receptor modulators. Clinical Pharmacokinectics. ,vol. 42, pp. 361- 372 ,(2003) , 10.2165/00003088-200342040-00004
Carl M. Sutherland, Larry A. Sternson, James H. Muchmore, John E. Ball, Elmo J. Cerise, Effect of impaired renal function on tamoxifen. Journal of Surgical Oncology. ,vol. 27, pp. 222- 223 ,(1984) , 10.1002/JSO.2930270404